Full Press Release Details
IceCure Granted Notice of Allowance for U.S.
Patent for its Next-Generation XSense Cryoprobes
The invention is designed to improve cryoprobe
extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience
XSense System with Cryoprobes recently
received regulatory approval in the U.S. and Israel
CAESAREA, Israel, September 18, 2025 - IceCure Medical
Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive
cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice
of Allowance from the U.S. Patent and Trademark Office for its patent titled "Cryoprobe".
"Our industry-leading liquid-nitrogen-based cryoablation platform
has been further advanced with this latest invention, a cryoprobe technology," stated IceCure's Chief Executive Officer, Eyal
Shamir. "There is an abundance of data, much of it from independent studies, showing that minimally invasive cryoablation procedures
with our flagship ProSense system have resulted in an improved patient experience with excellent medical outcomes. This new cryoprobe
technology, which is integrated in our next-generation XSense system, further reduces any potential risk of tissue trauma as the
cryoprobe is extracted from the patient at the end of the short, minimally invasive outpatient procedure."
This invention introduces a novel method for safely and efficiently
extracting the cryoprobe after tissue freezing during cryoablation procedures. The cryoprobe's tip is integrated with a heater,
temperature sensor, and controlled gas pulses, enabling precise estimation and management of the cryoprobe's external surface temperature-even
while embedded in frozen tissue. Designed to be compatible with a wide range of XSense system cryoprobe types, the new cryoprobe
technology is a versatile solution for multiple clinical scenarios.
About IceCure's Cryoablation Systems
IceCure's platform technology, including the ProSense Cryoablation
System and XSense Cryoablation System and CryoProbes, provides a minimally invasive treatment option to destroy tumors by freezing
them. The systems uniquely harness the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction
in benign and cancerous lesions, including breast, kidney, lung, and liver.
IceCure's cryoablation systems enhance patient and provider value by
accelerating recovery, reducing pain, surgical risks and complications. With easy, transportable design and liquid nitrogen utilization,
ProSense and XSense open the door to fast and convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense system
is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking
statements. For example, IceCure is using forward looking statements in this press release when it discusses: that data show
that minimally invasive cryoablation procedures with the ProSense system have resulted in an improved patient experience with excellent
medical outcomes and that the ProSense system reduces any potential risk of tissue trauma and the versatile prospective design compatibility
with a wide range of XSense system cryoprobe types. Historical results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors
that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and
its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the
United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners;
the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose
and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically
in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year
ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which
are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or
changes after the date of this release, except as required by law.